Funder
Otsuka Pharmaceutical Co., Ltd
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381–389
2. Committee for Medicinal Products for Human Use (CHMP) (2014) Abilify Maintena EMA Public Assessment Report (EPAR). European Medicines Agency website. https://www.ema.europa.eu/en/documents/assessment-report/abilify-maintena-epar-public-assessmentreport_en.pdf
3. Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM (2014) Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 205:135–144
4. Giordano G, Tomassini L, Cuomo I, Amici E, Perrini F, Callovini G, Carannante A, Kotzalidis GD, De Filippis S (2020) Aripiprazole long-acting injection during first episode schizophrenia-an exploratory analysis. Front Psych 10:935
5. Haddad PM, Brain C, Scott J (2014) Non-adherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5:43–62
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献